Concord Wealth Partners’s Royalty Pharma RPRX Stock Holding History

Concord Wealth Partners’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-40	Closed	-$1.09K	–	980
2023 Q3	$1.09K	Hold	40	–	–	﹤0.01%	936
2023 Q2	$1.23K	Hold	40	–	–	﹤0.01%	923
2023 Q1	$1.44K	Hold	40	–	–	﹤0.01%	856
2022 Q4	$1.58K	Buy	+40	New	+$1.67K	﹤0.01%	991
2022 Q3	–	Sell	-40	Closed	-$2K	–	927
2022 Q2	$2K	Hold	40	–	–	﹤0.01%	1056
2022 Q1	$2K	Hold	40	–	–	﹤0.01%	1130
2021 Q4	$2K	Hold	40	–	–	﹤0.01%	1159
2021 Q3	$1K	Hold	40	–	–	﹤0.01%	860
2021 Q2	$2K	Hold	40	–	–	﹤0.01%	914
2021 Q1	$2K	Buy	+40	New	+$1.9K	﹤0.01%	851

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Concord Wealth Partners's RPRX Position: Q4 2023 in Review

Concord Wealth Partners sold out of Royalty Pharma (RPRX) in Q4 2023, closing a stake of 40 shares — an estimated $1.09K sold.

Concord Wealth Partners first reported a position in RPRX in Q1 2021 and held it in 10 quarters. The position peaked at $2K in Q2 2022. 363 funds tracked by Wall St. Rank hold RPRX as of Q4 2023.

Concord Wealth Partners reported no remaining Royalty Pharma position as of Q4 2023 after selling out during the quarter.
Concord Wealth Partners sold 40 Royalty Pharma shares in Q4 2023, an estimated $1.09K.
Concord Wealth Partners first reported a position in Royalty Pharma in Q1 2021 and held it in 10 quarters.
Concord Wealth Partners's Royalty Pharma position peaked at $2K in Q2 2022.
363 funds tracked by Wall St. Rank held Royalty Pharma as of Q4 2023.

Based on Concord Wealth Partners's 13F filing for Q4 2023, filed 6 Feb 2024.